Table 4.
Outcome of all patients with differentiated thyroid carcinoma.
| Total (%) | Prepubertal | Pubertal/postpubertal | p-value | |
|---|---|---|---|---|
| N = 85 | N = 20 (24%) | N = 65 (76%) | ||
| Pathological findings in I-131 post-therapeutic scan | 14 (20%) | 6 (30%) | 8 (12%) | 0.069 |
| • Iodine uptake in lymph node metastases: | 8 | 4 | 4 | |
| • Iodine uptake in distant metastases: | 6 (N = 5 pulmonary, N = 1 bone) | 2 (N = 2 pulmonary) | 4 (N = 3 pulmonary; N = 1 bone) | |
| • Non-iodine avid metastases: | 2 (N = 2 pulmonary) | 2 (N = 2 pulmonary) | 0 | |
| Outcome after 1 year | ||||
| • Not available | 4 | 1 | 3 | |
| • NED | 39 (48%) | 8 (42%) | 31 (50%) | 0.607 |
| • ED | 42 (52%) | 11 (58%) | 31 (50%) | |
| Follow-up | ||||
| • Not available | 5 | 1 | 4 | |
| • Complete remission | 61 (76%) | 11 (58%) | 50 (82%) | 0.044 |
| • Partial remission | 10 (13%) | 5 (26%) | 5 (8%) | |
| • Stable disease | 8 (10%) | 2 (11%) | 6 (10%) | |
| • Progressive disease • Recurrence |
1 (1%) 0/39 |
1 (5%) 0/8 |
0 0/31 |
|
| Last visit of follow-up | ||||
| • Not available | 5 | 1 | 4 | |
| • NED/ER | 61 (76%) | 11 (58%) | 50 (82%) | 0.06 |
| • ED | 19 (24%) | 8 (42%) | 11 (18%) | |
| o Indeterminate response | 10 | 3 | 7 | 0.105 |
| o Biochemical incomplete response | 1 | 1 | 0 | |
| o Structural incomplete response | 8 | 4 | 4 | |
| End of the study | ||||
| • Not available | 5 | 1 | 4 | |
| • Survivors | 79 | 19 | 60 | 0.838 |
| • Death | 1 (not cancer-related) | 0 | 1 | |
ED, evidence of disease; NED, no evidence of disease; ER, excellent response.